Navigation Links
B. Braun Anticipates Becoming First to Deliver FDA Approved 2g Cefazolin
Date:6/2/2009

Approval for Antibiotic Delivered in DUPLEX Delivery System Pending

BETHLEHEM, Pa., June 2 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, said today it anticipates U.S. Food and Drug Administration (FDA) approval for 2g Cefazolin for Injection USP and Dextrose Injection USP in B. Braun's DUPLEX(R) Drug Delivery System.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO )

The FDA approval will make B. Braun the first company to deliver an FDA approved 2g Cefazolin dose to hospitals and other healthcare settings where it is a frequently prescribed antibiotic.

The arrival of 2g Cefazolin will be welcome news in hospital emergency rooms, operating suites and outpatient surgical centers. Until now, Cefazolin had only been available in 1g IV and multi-dose vials. The 2g Cefazolin in the DUPLEX(R) system can be stored, ready to use wherever and whenever it is needed, which means faster, safer and more accurate administration of 2g Cefazolin to patients.

"B. Braun heard physician and pharmacist calls for a 2g Cefazolin dose and we've responded," said Rob Albert, Vice President, Pharma Marketing for B. Braun. "2g Cefazolin will be the latest in an expanding DUPLEX(R) portfolio, which is designed to provide fast, safe, convenient and Joint Commission and USP Chapter < 797 > compliant products that improve the practice of healthcare professionals while advancing patient safety and outcomes."

Frequently used in emergency rooms, operating suites and ambulatory surgery centers, B. Braun will offer 2g Cefazolin delivered via its DUPLEX(R) Delivery System, a ready-to-use two-compartment flexible plastic IV container that stores pre-measured drug and diluent doses. Healthcare workers administering DUPLEX(R) simply squeeze the container and shake it to mix pharmaceuticals and diluent.

The DUPLEX(R) system saves time, labor and speeds dispensing because it can be stored right in emergency and operating rooms until it's needed and is ready immediately. Its PVC-free construction makes it eco-friendly while its DEHP-free and Latex-free construction makes it patient-friendly. A barcode that references the final admixture, lot number and expiration date helps reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking.

With the addition of 2g Cefazolin to its drug delivery portfolio, B. Braun will expand its broad spectrum of intravenous cephalosporin antibiotic therapies for the hospital setting: Cefoxitin, CefTRIaxONE, 1g Cefazolin, CefUROXime and Cefotetan.

Customers interested in more information can call: 888.422.7286 (888.4BBRAUN).

About DUPLEX

The DUPLEX(R) Drug Delivery System is a revolutionary system designed to simplify intravenous antibiotic delivery to patients, minimize the potential for medication errors, eliminate the pharmacy labor component of IV antibiotic delivery and reduce drug waste.

Consisting of a pre-filled, DEHP-free, PVC-free, Latex-free IV bag containing proper doses of drug and diluent in different compartments separated by a quick release seal, DUPLEX(R) can be stored at room temperature and does not require a messy thawing process. The caregiver simply squeezes the bag to mix the drug and diluent just prior to administration. Special oxygen and moisture barrier technologies are employed to protect the drug powder from vapor and oxygen transfer through the bag over the product's shelf life.

About B. Braun

B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise(R)" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.

Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, e-mail us at inquiry.us@bbraun.com or visit B. Braun at www.bbraunusa.com.


'/>"/>
SOURCE B. Braun Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NxStage Extends Supply Agreement with B. Braun Medical Inc. to Include Streamline(R) Technology
2. B. Braun Wins Premier Contract for Full Line of Dialysis Products
3. B. Braun Medical Inc. Launches Home Infusion Therapy Web Site
4. Be Green with B. Braun: Company Shares Expertise, Environmentally Responsible Products at ASHP 2008
5. Writing a Prescription for Safety: B. Braun CAPS(R) Announces New Advancements at ashp 2008
6. B. Brauns DoseTrac(TM) Software: Making Connections to Better Manage IV Therapy
7. B. Braun Medical Inc. Launches Ambulatory Surgical Center Website
8. The SCOOTER Store Donates Power Wheelchair to New Braunfels Car Crash Victim
9. Scooter Store Executives to Deliver Power Wheelchair Donation to New Braunfels Car Crash Victim
10. 22nd Annual Braun Industries/ZOLL Medical EMT/Paramedic of the Year Announced
11. Braun Challenges Business School Talent To Create A Buzz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 19, 2017 , ... In 2009, Carol Bryan endured immense ... severe facial disfiguration. After four frightening years of isolation and emotional and physical ... who removed the substances in a partial facial transplant through eight surgeries. ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... panel system. , The Tranquility privacy panel system was designed to deliver ... Tranquility panels help reduce noise and provide the visual privacy required to maintain ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sam & Associates Insurance ... commercial and residential clients in the California Bay Area, is launching a charity drive ... the region. , Heart disease is the primary killer of adult men and women ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the ... Lawrenceville, New Jersey and the surrounding area, is inaugurating a charity event ... more commonly known as Lou Gehrig's disease or motor neurone disease, is a ...
(Date:1/19/2017)... ... January 19, 2017 , ... Creative messages ... Real Impact contest from Impact Teen Drivers and California Casualty. Entries from students ... , Educational grants totaling $15,000 will be awarded for the best peer-to-peer messages ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... LONDON , January 19, 2017 Incretin ... Sympathomimetics and Others The global anti-obesity drugs ... the first half of the forecast period and CAGR of 38.7% ... expected to grow at a CAGR of 32.8% from 2016 to ... million in 2021, and $24,063 million in 2027. ...
(Date:1/19/2017)... Jan. 19, 2017  Sensus Healthcare, Inc. (NASDAQ: ... specializing in the treatment of non-melanoma skin cancers ... superficial radiation therapy, today announced that it will ... financial results on Thursday, February 2, 2017 after the ... a conference call with the investment community on Thursday, ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... New Therapeutic Option to Address Motor Symptoms and ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... Fabrizio Stocchi , European Neurological Review,2016;11(Suppl. 2): 2-15, ...
Breaking Medicine Technology: